Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-04-20 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia has submitted a phase I clinical trial application for its second project, CAN10
Regulatory Filings Classification · 100% confidence The document announces that Cantargia has submitted a phase I clinical trial application for its project CAN10, detailing the drug, target diseases (systemic sclerosis and myocarditis), trial location (Germany), and expected start time (mid-2023). It includes contact information and boilerplate 'About' sections. Crucially, the document ends with an attachment link titled with the announcement's headline. Given the short length (4457 chars) and the nature of the content—an announcement about a regulatory submission rather than the submission document itself—this fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since it is a specific announcement about a clinical trial application submission, which is a regulatory event, and it is not one of the highly specific financial reports (like 10-K, ER, IR), RNS is the most appropriate fallback for a general regulatory announcement not covered elsewhere. However, since it is an announcement of a specific regulatory action (submission of a trial application), and it is not a standard financial report, RNS is the best fit as a general regulatory filing announcement.
2023-04-20 English
Cantargia har lämnat in ansökan om klinisk fas I-studie för dess andra projekt, CAN10
Regulatory Filings Classification · 100% confidence The document is a press release from Cantargia announcing that they have submitted an application to start a Phase I clinical trial for their drug candidate CAN10. The text details the drug, the planned study (safety, pharmacokinetics, biomarkers), and the expected timeline. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is an announcement regarding clinical development progress. Since it is a specific announcement about a corporate/development event that doesn't fit perfectly into the other specific categories (like M&A, Dividend, or Director's Dealing), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, especially those related to regulatory submissions or clinical milestones, as mandated by the EU Market Abuse Regulation mentioned at the end.
2023-04-20 Swedish
Cantargia presents anti-metastatic effects of nadunolimab in cancer models at AACR 2023
Legal Proceedings Report Classification · 99% confidence The document is a press release from Cantargia announcing the presentation of preclinical data for its asset nadunolimab at the AACR 2023 meeting. It details scientific findings, quotes the CEO, and provides contact information and company background. This type of announcement, which disseminates research findings or corporate news outside of mandatory financial reporting cycles (like 10-K or ER), typically falls under general regulatory announcements or investor relations material. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific management/governance filing (MANG, DIRS, DEF 14A), nor a transcript (CT), it best fits the category for general regulatory/investor news dissemination. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, yet important, corporate updates that are publicly released, especially when they relate to research milestones. It is not an announcement of a report publication (RPA) because it *is* the content of the announcement, not just a notice that a report is available.
2023-04-19 English
Cantargia presenterar anti-metastaserande effekter av nadunolimab i cancermodeller på AACR 2023
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia AB announcing the presentation of preclinical data for their drug nadunolimab at the AACR 2023 conference. It details scientific findings, quotes the CEO, and provides contact information and company background. This type of announcement, which communicates scientific progress, clinical trial updates, and research findings to the public and investors, is best classified as an Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the detailed scientific content and focus on presenting research results (even if the presentation itself occurred elsewhere), 'Investor Presentation' (IP) is a strong fit, as these releases often serve as the primary communication vehicle for such data to the investment community. It is not a formal regulatory report like 10-K or IR, nor is it a simple announcement of a report's publication (RPA). Since it details research findings intended for investors, IP is the most appropriate specific category.
2023-04-19 Swedish
Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer
Regulatory Filings Classification · 95% confidence The document is a press release announcing the presentation of new clinical data (efficacy and subgroup analyses for nadunolimab in pancreatic cancer) at the AACR 2023 meeting. It contains key financial/clinical results, quotes from the CEO, tables summarizing efficacy parameters, and references to future events (R&D Day). It concludes with a statement about being obliged to make the information public pursuant to the EU Market Abuse Regulation and includes links to attachments. This format strongly suggests an official company announcement of material, non-public information, which is typically classified as an Earnings Release (ER) if it contains results, or a Regulatory Filing (RNS) if it's a general disclosure. Since it details specific clinical results and is framed as an update on development progress, it aligns best with an Earnings Release (ER) which often includes operational/clinical milestones alongside financial highlights, or potentially a Regulatory Filing (RNS) if it's purely regulatory disclosure. Given the detailed presentation of clinical efficacy data and the context of a major conference presentation, ER is a strong candidate, but the final sentence points towards a general regulatory disclosure obligation. However, the content is highly specific clinical data presentation, not a standard quarterly earnings summary. Since it is a detailed announcement of clinical trial results presented at a conference, and it is not a full report (like 10-K or IR), it fits the description of a significant corporate update. In many databases, detailed clinical updates presented outside of standard quarterly reports are often categorized as Regulatory Filings (RNS) or sometimes Investor Presentations (IP) if it were the presentation itself. Since this is the *announcement* of the data presentation, and it is a mandatory disclosure under MAR, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a material, non-standard report announcement, especially when ER is usually reserved for periodic financial results. Given the structure and the explicit mention of EU Market Abuse Regulation compliance, RNS is the safest classification for a material, non-standard announcement.
2023-04-17 English
Cantargia presenterar nya kliniska data på AACR 2023 som kraftfullt stöder utvecklingen av nadunolimab i bukspottkörtelcancer
Earnings Release Classification · 98% confidence The document is a press release announcing the presentation of new clinical data for the drug nadunolimab at the AACR 2023 conference. It details interim efficacy data, subgroup analyses, survival statistics (OS, PFS), and response rates for pancreatic cancer patients. This type of announcement, focusing on clinical trial results and scientific presentation, is characteristic of an Earnings Release (ER) if it were summarizing period results, or more specifically, a general announcement related to research and development progress. Since it is a detailed announcement of clinical data presented at a scientific meeting, it aligns best with an Earnings Release (ER) which often includes key operational and R&D updates, or potentially an Investor Presentation (IP) if it were the presentation itself. However, the structure is that of a formal press release announcing results, which is the primary function of an Earnings Release (ER) in many contexts, even if the core content is scientific data rather than quarterly financials. Given the options, and the fact that it is a formal announcement of key performance indicators (clinical efficacy), ER is a strong candidate. Alternatively, since it is a detailed scientific update, it could be considered an Investor Presentation (IP) if the content were structured as slides, but this is a narrative press release. The document concludes with a notice about an upcoming R&D day webcast, further suggesting an investor/market communication. Since it is not a full quarterly report (10-K or IR) and not explicitly a presentation file (IP), the most fitting category for a major announcement of clinical trial results is Earnings Release (ER), as these releases often contain the most significant operational/R&D news impacting the company's outlook. It is not a Report Publication Announcement (RPA) because it contains the substantive data itself, not just a notice that a report is available. FY 2023
2023-04-17 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.